Boston, MA 10/15/2014 (wallstreetpr) – Novavax, Inc. (NASDAQ:NVAX) has initiated second phase clinical trial of its study concerning the evaluation of respiratory syncytial virus (RSV) vaccine on pregnant women.
Aim Of The Study
As briefed in the article, the biopharmaceutical company has started enrollment in the second phase of the RSV F-protein nanoparticle vaccine. Healthy women in the third trimester of their pregnancy have been chosen as subjects for the study.
The study aims at evaluating the immunogenicity and safety of the vaccine in the subjects. It seeks to assess the effect of maternal immunization on the safety of the infant for a period of 12 months. In addition, the trial will also determine the levels of RSV-specific antibodies generated over a six-month period.
In relation to this, the President and Chief Executive Officer of Novavax, Inc. (NASDAQ:NVAX), Stan Erck, believes the start of the trial to be a watershed event for the company. The company seeks to improve infant health, and this achievement marks an important milestone in this direction, commented the Senior Vice President of the company’s research and development unit, Greg Glenn.
RSV And RSV Vaccine
RSV is one the most important factors in infant morbidity and mortality across the world. It is a key respiratory pathogen and poses a great threat to the infant, as well as the elderly population. Novavax attempts to develop a vaccine to be administered to women when they are still pregnant to benefit the infant. The company sees this as the best means to protect newly born children as they are prone to fatal diseases linked with RSV.
Novavax, Inc. (NASDAQ:NVAX) has adopted an organized and disciplined approach in the development of the vaccine. The enrollment in the trial underlines its step-by-step plan and stands out as a significant inflection point. The company had also followed the approach in the development of other immunogenicity and clinical safety evaluating trials. One such drug was the palivizumab (Synagis™).